Long-acting antipsychotics as a factor for improving treatment adherence in schizophrenia: case report

Authors

  • Victor Siciliano Soares Programa de Esquizofrenia (PROESQ), Universidade Federal de São Paulo (UNIFESP), São Paulo, SP.
  • Claudiane Salles Daltio Programa de Esquizofrenia (PROESQ), Universidade Federal de São Paulo (UNIFESP), São Paulo, SP.
  • Cecília Attux Programa de Esquizofrenia (PROESQ), Universidade Federal de São Paulo (UNIFESP), São Paulo, SP. https://orcid.org/0000-0001-9159-2344

DOI:

https://doi.org/10.25118/2763-9037.2014.v4.258

Keywords:

Antipsychotics, schizophrenia, treatment adherence

Abstract

This article describes the case of a young patient in his first psychotic episode and facing difficulties adhering to treatment, in which second-generation long-acting antipsychotics were used. The use of these drugs should be more often considered in the treatment of schizophrenia, due to their easy handling and safety, as they improve treatment adherence and consequently the prognosis of patients.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 1999;46:729-39. https://doi.org/10.1016/S0006-3223(99)00147-X DOI: https://doi.org/10.1016/S0006-3223(99)00147-X

Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886-91. https://doi.org/10.1176/appi.ps.55.8.886 DOI: https://doi.org/10.1176/appi.ps.55.8.886

Kaplan G Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171-80. https://doi.org/10.2147/PPA.S53795 DOI: https://doi.org/10.2147/PPA.S53795

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antip¬sychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-23. https://doi.org/10.1056/NEJMoa051688 DOI: https://doi.org/10.1056/NEJMoa051688

Waddell L, Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl. 2009;52:S43-50. https://doi.org/10.1192/bjp.195.52.s43 DOI: https://doi.org/10.1192/bjp.195.52.s43

Manchanda R, Chue P, Malla A, Tibbo P, Roy MA, Williams R, et al. Long-acting injectable antipsychotics: evidence of effectiveness and use. Can J Psychiatry. 2013;58:5S-13S. https://doi.org/10.1177/088740341305805s02 DOI: https://doi.org/10.1177/088740341305805s02

Attard A, Olofinjana O, Cornelius V, Curtis V, Taylor D. Paliperidone palmitate long-acting injection-prospective year-long follow-up of use in clinical practice. Acta Psychiatr Scand. 2014;130:46-51. https://doi.org/10.1111/acps.12201 DOI: https://doi.org/10.1111/acps.12201

Published

2014-10-31

How to Cite

1.
Soares VS, Daltio CS, Attux C. Long-acting antipsychotics as a factor for improving treatment adherence in schizophrenia: case report. Debates em Psiquiatria [Internet]. 2014 Oct. 31 [cited 2024 Dec. 23];4(5):32-4. Available from: https://revistardp.org.br/revista/article/view/258

Conference Proceedings Volume

Section

Case Report

Plaudit

Similar Articles

You may also start an advanced similarity search for this article.